CatalystPit
TerminalPit ConsensusInsidersPoliticiansInstitutionsNewsScreener

PTCTPTC THERAPEUTICS, INC.

NASDAQ · PHARMACEUTICAL PREPARATIONS
Last close $64.78 · 2026-09-30
ABOUT
ExchangeNASDAQ
SectorHealthcare
IndustryPHARMACEUTICAL PREPARATIONS
Market cap$5.41B
CountryUSA
RECENT INSIDER TRADES
  • 2026-10-09 · SCHMERTZLER MICHAEL (Director) · SELL
  • 2026-10-07 · Boulding Mark Elliott (EXEC. VP AND CLO) · SELL
  • 2026-10-07 · Boulding Mark Elliott (EXEC. VP AND CLO) · OTHER
INSTITUTIONAL OWNERSHIP
Institutional holders405
Shares held129,165,103
Value$9.56B
Percent of shares outstanding154.76%
As of quarter end2026-06-30
RECENT NEWS
  • PTC Therapeutics director Michael Schmertzler sells $158k in shares
  • PTC Therapeutics CLO Mark Boulding sells $132,790 in shares
  • RBC Capital reiterates PTC Therapeutics stock rating at Sector Perform
  • PTC Therapeutics approves stock options for 51,270 shares and 37,995 RSUs
  • PTCT: PTC to acquire ST-920 Fabry Disease Gene
CatalystPit
FeaturesComing soonPricingComing soonPrivacyTermsDisclaimerAffiliate TermsContact
2026 CATALYSTPIT · NOT FINANCIAL ADVICE · DELAYED FILINGS
PTC THERAPEUTICS, INC. (PTCT) · Stock Price, Insider Trades, Institutional Holdings · CatalystPit